Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow cell graft engineering: from bench to bedside.

P M Chilton1, Y Huang, S T Ildstad

  • 1Institute for Cellular Therapeutics, Department of Surgery, University of Louisville School of Medicine, KY 40202-1760, USA.

Leukemia & Lymphoma
|May 9, 2001
PubMed
Summary

Graft facilitating cells (FC) enable successful bone marrow transplantation (BMT) in mismatched recipients by ensuring hematopoietic stem cell (HSC) engraftment without graft-versus-host disease (GVHD) or graft failure. This breakthrough expands BMT applications for non-malignant diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of Human CD8(+)TCR(-) Facilitating Cells In Vitro and In Vivo in a NOD/SCID/IL2rγ(null) Mouse Model.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Regulatory B cells: the new "it" cell.

Transplantation proceedings·2013
Same author

Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance.

Clinical pharmacology and therapeutics·2012
Same author

Immunology of vascularized composite allotransplantation: a primer for hand surgeons.

The Journal of hand surgery·2012
Same author

Vascularized composite allotransplantation research: the emerging field.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2012
Same author

Vascularized composite allotransplantation at a crossroad.

Transplantation proceedings·2011

Area of Science:

  • Immunology
  • Hematology
  • Transplantation Biology

Background:

  • Bone marrow transplantation (BMT) offers potential treatments for hemoglobinopathies, autoimmune diseases, and enzyme deficiencies.
  • Graft-versus-host disease (GVHD) and graft failure are significant limitations to BMT's therapeutic use.
  • Current methods to control GVHD often increase graft failure rates, especially in mismatched or older recipients.

Purpose of the Study:

  • To characterize a novel cell population that facilitates hematopoietic stem cell (HSC) engraftment in allogeneic recipients.
  • To develop strategies for engineering bone marrow cells (BMC) to overcome the allogeneic barrier and prevent GVHD.
  • To expand the therapeutic potential of BMT for non-malignant conditions.

Main Methods:

  • Phenotypic and functional characterization of novel graft facilitating cells (FC) within bone marrow.

Related Experiment Videos

  • Engineering of donor bone marrow cells (BMC) to retain both HSC and FC while depleting T cells.
  • Evaluation of engraftment, GVHD, and graft failure in allogeneic transplantation models.

    • Main Results:

    • Discovery of FC populations that restore the engraftment potential of purified HSC in allogeneic settings.
    • Addition of FC to T cell-depleted BMC grafts resulted in successful allogeneic engraftment without GVHD or graft failure.
    • New BMC engineering strategies utilizing FC enabled engraftment in mismatched and older recipients.

    Conclusions:

    • FC technology represents a significant advancement in BMT, enabling engraftment across genetic disparities.
    • This approach overcomes major hurdles of GVHD and graft failure, expanding BMT eligibility.
    • FC-mediated BMT holds broad potential for treating a wide range of non-malignant diseases.